Manufacturer of Controlled Substances, Notice of Application, Nektar Therapeutics, 43862-43863 [2012-18203]
Download as PDF
<![CDATA[
43862
Federal Register / Vol. 77, No. 144 / Thursday, July 26, 2012 / Notices
material are not appropriate. 72 FR 3417
(2007).
DEA has considered the factors in 21
U.S.C. 823(a) and 952(a), and
determined that the registration of
Noramco Inc. to import the basic classes
of controlled substances is consistent
with the public interest, and with
United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Noramco, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 27, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
and determined that the registration of
Alltech Associates, Inc. to import the
basic classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Alltech Associates, Inc.
to ensure that the company’s
registration is consistent with the public
interest.
The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18213 Filed 7–25–12; 8:45 am]
[FR Doc. 2012–18220 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18210 Filed 7–25–12; 8:45 am]
Drug Enforcement Administration
Drug Enforcement Administration
BILLING CODE 4410–09–P
Importer of Controlled Substances;
Notice of Registration; Alltech
Associates, Inc.
Importer of Controlled Substances;
Notice of Registration; Noramco, Inc.
DEPARTMENT OF JUSTICE
By Notice dated May 15, 2012, and
published in the Federal Register on
May 25, 2012, 77 FR 31387, Alltech
Associates, Inc., 2051 Waukegan Road
Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
TKELLEY on DSK3SPTVN1PROD with NOTICES
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
Heroin (9200) ...............................
Cocaine (9041) .............................
Codeine (9050) .............................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
I
I
I
II
II
II
II
II
II
The company plans to import these
controlled substances for the
manufacture of reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
VerDate Mar<15>2010
16:42 Jul 25, 2012
Jkt 226001
By Notice dated May 15, 2012, and
published in the Federal Register on
May 25, 2012, 77 FR 31388, Noramco,
Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances:
Drug
Schedule
Phenylacetone (8501) ..................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Tapentadol (9780) ........................
II
II
II
II
The company plans to import the
Opium (9600) and Poppy Straw
Concentrate (9670) to manufacture other
controlled substances. The company
plans to import Tapentadol (9780) in the
intermediate form for the bulk
manufacture of Tapentadol, which it
will distribute to its customers. The
company plans to import the
Phenylacetone (8501) in bulk for the
manufacture of a controlled substance.
Comments and requests for hearings
on applications to import narcotic raw
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application,
Nektar Therapeutics
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 26, 2012,
Nektar Therapeutics, 1112 Church
Street, Huntsville, Alabama 35801,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Fentanyl (9801), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance in
support of product development.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
E:\FR\FM\26JYN1.SGM
26JYN1
43863
Federal Register / Vol. 77, No. 144 / Thursday, July 26, 2012 / Notices
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18203 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cambrex Charles City, Inc.
[FR Doc. 2012–18212 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 4, 2012,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
TKELLEY on DSK3SPTVN1PROD with NOTICES
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
4-Anilino-N-phenethyl-4-piperidine
(ANPP)(8333).
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium, raw (9600) .......................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Poppy Straw Concentrate (9670)
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
II
II
II
II
II
II
II
II
II
II
II
II
16:42 Jul 25, 2012
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Boehringer Ingelheim Chemicals Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 8, 2012,
Boehringer Ingelheim Chemicals Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805–9372, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Schedule
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Tapentadol (9780) ........................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 226001
DEPARTMENT OF JUSTICE
Drug
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers, for dosage form
development, for clinical trials, and for
use in stability qualification studies.
Any other such applicant, and any
person who is presently registered with
VerDate Mar<15>2010
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for formulation
into finished pharmaceuticals. In
reference to Methadone Intermediate
(9254) the company plans to produce
Methadone HCL active pharmaceutical
ingredients (APIs) for sale to its
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
PO 00000
Frm 00059
Fmt 4703
Sfmt 9990
Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration
[FR Doc. 2012–18202 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration,
Cambrex Charles City, Inc.
By Notice dated April 17, 2012 and
published in the Federal Register on
April 26, 2012, 77 FR 24986, Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Hydrocodone (9193) .....................
Methadone (9250) ........................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–18209 Filed 7–25–12; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 77, Number 144 (Thursday, July 26, 2012)]
[Notices]
[Pages 43862-43863]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-18203]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances, Notice of Application,
Nektar Therapeutics
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 26, 2012, Nektar
Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Fentanyl (9801), a basic class
of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance in
support of product development.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative
[[Page 43863]]
(ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be
filed no later than September 24, 2012.
Dated: July 17, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-18203 Filed 7-25-12; 8:45 am]
BILLING CODE 4410-09-P
